Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole 40 mg versus continued proton pump inhibitor therapy after initial treatment failure in GERD
2005-000458-57Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esomeprazole, omeprazole, lansoprazole, rabeprazole and pantoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of patients free from heartburn after 4 weeks. Started Apr 2005; status: completed.
02
Drugs
esomeprazoleomeprazolelansoprazolerabeprazolepantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2005-000458-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000458-57.